Optimization of bifunctional piperidinamide derivatives as σ 1 R Antagonists/MOR agonists for treating neuropathic pain.

Here, we describe the optimization, synthesis, and associated pharmacological analgesic activities of a new series of bifunctional piperidinamide derivatives as sigma-1 receptor (σ ₁ R) antagonists and mu opioid receptor (MOR) agonists. The new compounds were evaluated in vitro in σ ₁ R and MOR binding assays. The most promising compound 114 (also called HKC-126), showed superior affinities for σ ₁ R and MOR and good selectivity to additional receptors related to pain. Compound 114 showed powerful dose-dependent analgesic effects in the acetic acid writhing test, formalin test, hot plate test, and chronic constriction injury (CCI) neuropathic pain model. In contrast to an equianalgesic dose of fentanyl, compound 114 produced fewer opioid-like side effects, such as reward liability, respiratory depression, physical dependence, and sedation. Lastly, the pharmacokinetic properties of this drug were also acceptable, and these results suggest that compound 114, as a mixed σ ₁ R/MOR ligand, has potential for treating neuropathic pain.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 Elsevier Masson SAS. All rights reserved.)